Biosimilars Drive Savings in Medicare’s Oncology Care Model
Three Ways COVID-19 Makes the Oncology Care First Model More Attractive
COVID-19 has delayed the transition to Oncology Care First, but the forthcoming model could help.
Rethinking Downside Risk Protection Amid Growth in Precision Medicine
Oncology drug costs affect those entering into risk-based arrangements, and these groups must rethink their approach to evaluating risk.
